






Redeye Growth Day June 2, 2021

Pontus Nobréus  
CEO




# Global burden of kidney failure – large impact on the individual and society




 Number of people receiving KRT  
 Number of people needing KRT  
 KRT: Kidney Replacement Therapy

## Medicare spending for ESRD beneficiaries

ESRD beneficiaries comprise less than

**1%**   
of the total Medicare population



SOURCE: 2018 U.S. Renal Data System Annual Data Report.

*“Many developed countries spend 2–3% of their health care budgets on treatment for patients with ESKD, even though these patients comprise just 0.1–0.2% of the total population.”*


ESKD: end-stage kidney disease

# Challenges with kidney transplantations

Gap between supply and demand


**Patients on the Waiting List vs. Transplants Performed**

By Organ in 2020




\*Other includes allograft transplants like face, hands, and abdominal wall.

ABO incompatible blood groups




Kidney Paired Donation (KPD)





# Glycosorb® ABO enables transplantations regardless of blood group



In clinical use since 2001 > 60 publications

- > 5,000 transplantations
- ~ 30 countries
- Living Donor Kidney transplantations performed with Glycosorb® ABO is estimated to save 700,000 dialysis treatments per year

Glycosorb® ABO for transplantations of:

- Kidney
- Liver
- Heart
- Lung
- Stem cells



[J Nephrology](#). 2016 Jul; 5(3): 90–97.

Published online 2016 Jun 29. doi: [10.15171/jnp.2016.17](#)

PMCID: PMC4961822

PMID: [27540536](#)

Treatment of large plasma volumes using specific immunoadsorption to desensitize ABO-incompatible kidney-transplant candidates

**Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational**

o, <sup>1</sup> [Nicolas Doumerc](#), <sup>4</sup>

#### TEMA TRANSPLANTATION

## Blodgruppsinkompatibla njurar kan transplanteras

ABO-inkompatibilitet är inte längre ett hinder för njurtransplantation.

Gunnar Tydén, professor, överläkare, transplantationskirurgiska kliniken, Karolinska universitetssjukhuset, Stockholm  
gunnar.tyden@karolinska.se

Gunnela Nordén, docent, överläkare, Transplantationscentrum, Sahlgrenska universitetssjukhuset, Göteborg


Ali-Reza Biglarnia, med dr, överläkare, transplantationskirurgiska enheten, Akademiska sjukhuset, Uppsala

Peter Björk, med dr, överläkare, njur- och transplantationskliniken, Skånes universitetssjukhus, Malmö


ch, Michael  
Emmerich, Gerd

# Global transplantations by the numbers


> 150,000 Transplantations 2019




~ 98,000 Kidney Transplantations 2019  
(Deceased and Living Donors)



# Glycosorb® ABO - large market potential Living Donor Kidney transplantations



Geographical distribution of number of Living Donor Kidney transplantations 2019



USA  
~160 MSEK


Europe  
~100 MSEK

India, Mexico  
& Turkey  
~150 MSEK

Living Donor Kidney ABO incompatible transplantations  
Estimated global market potential for Glycosorb® ABO


**~ 600 MSEK**

## Increasing number of blood group incompatible transplantations with Glycosorb® ABO





# Glycosorb® ABO – designed to enable access to universal blood plasma



## Glycosorb® ABO makes it possible to:

- Improve stock keeping and logistics for the blood bank
- Reduce risk for transfusion mistakes and delays
- Provide access to adequate blood plasma in emergency situations
- Increase the availability of COVID-19 convalescent plasma by removing the blood group barrier

Estimated market for universal blood plasma in EU:  
> 1 billion SEK per year

## R&D Pipeline – focus on autoimmune diseases



### **Rheumatoid Arthritis (RA)**


- 5 million people in EU
- No cure – immunosuppressive and anti-inflammatory drugs – up to 10% do not respond
- Potential market in EU estimated to 5 billion SEK per year
- Biocompatibility studies completed with good results
- Next step clinical study on RA-patients

### **Other projects**


- Myasthenia Gravis (MG)
  - Impact on muscle function
  - Typically treated with plasma exchange
  - > 100 000 people in the US and Europe
- HLA
- Galectins

# Financials

Net sales 2016-2020 (MSEK)



Net income 2016-2020 (MSEK)



Interim report


January-March 2021  
Glycorex Transplantation AB (publ)

Quarter 1, 2021

- Net sales: 4.9 (7.7) MSEK
- Net income: -5.3 (0.3) MSEK
- Earnings per share: -0.07 (0.00) SEK
- Cash position: 44.7 (56.2) MSEK

*Positive sales development after weak start of the year*

*Covid-19 continued to affect sales in Q1, 2021*







Thank you!

Q&A

